Somerville Kurt F Sells 1,202 Shares of Illumina, Inc. (NASDAQ:ILMN)

Somerville Kurt F trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 23,261 shares of the life sciences company’s stock after selling 1,202 shares during the quarter. Illumina comprises about 1.7% of Somerville Kurt F’s portfolio, making the stock its 27th biggest holding. Somerville Kurt F’s holdings in Illumina were worth $8,563,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. Greenleaf Trust lifted its position in shares of Illumina by 0.6% during the 2nd quarter. Greenleaf Trust now owns 6,691 shares of the life sciences company’s stock worth $2,463,000 after buying an additional 42 shares during the last quarter. Texas Yale Capital Corp. bought a new stake in shares of Illumina during the 2nd quarter worth $671,000. James Investment Research Inc. bought a new stake in shares of Illumina during the 2nd quarter worth $103,000. Daiwa Securities Group Inc. lifted its position in shares of Illumina by 34.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 9,571 shares of the life sciences company’s stock worth $3,523,000 after buying an additional 2,473 shares during the last quarter. Finally, Arcadia Investment Management Corp MI lifted its position in shares of Illumina by 788.8% during the 2nd quarter. Arcadia Investment Management Corp MI now owns 2,533 shares of the life sciences company’s stock worth $933,000 after buying an additional 2,248 shares during the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.

In other news, SVP Omead Ostadan sold 1,260 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $315.32, for a total value of $397,303.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 1,220 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $309.70, for a total value of $377,834.00. Following the completion of the sale, the senior vice president now directly owns 8,006 shares of the company’s stock, valued at approximately $2,479,458.20. The disclosure for this sale can be found here. In the last three months, insiders sold 61,167 shares of company stock valued at $19,899,477. Insiders own 0.38% of the company’s stock.

Several equities analysts have commented on the company. Cowen dropped their target price on Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, July 12th. Credit Suisse Group reiterated a “buy” rating and issued a $340.00 target price on shares of Illumina in a research report on Wednesday. Canaccord Genuity downgraded Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $330.00 to $300.00 in a research report on Tuesday, July 30th. Wolfe Research assumed coverage on Illumina in a research report on Thursday, May 30th. They issued an “outperform” rating for the company. Finally, ValuEngine downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $330.92.

Shares of ILMN stock traded down $4.28 on Friday, hitting $297.38. The company had a trading volume of 1,027,137 shares, compared to its average volume of 1,782,099. The stock has a market cap of $44.34 billion, a price-to-earnings ratio of 51.99, a P/E/G ratio of 2.81 and a beta of 1.11. The company’s 50-day moving average price is $335.61. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.33 and a current ratio of 6.79. Illumina, Inc. has a twelve month low of $268.62 and a twelve month high of $380.76.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.03. The company had revenue of $838.00 million during the quarter, compared to analysts’ expectations of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.43 earnings per share. As a group, analysts expect that Illumina, Inc. will post 6.04 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: What is Depreciation?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.